Curespec

Curespec Curespec offers a medical device solution that treats hypertension and chronic kidney disease (CKD). and Europe. https://www.curespec.info/

Curespec,
Reducing Blood Pressure
Curing the Kidneys
A groundbreaking solution that targets chronic kidney disease and hypertension, two critical health challenges affecting over 700 million individuals globally. These conditions drastically reduce the quality of life for those affected. The addressable market for Curespec's solution is substantial, estimated at $16.7 billion across the U.S. Our fully developed and CE-marked product leverages Electro-Hydraulic Acoustic Therapy (eHAT) to transform treatment for hypertension and chronic kidney disease. Curespec's innovative therapy reduces blood pressure and enhances kidney function by rejuvenating renal tissue to promote kidney health. Clinical data reveal that 90% of patients maintain their eGFR levels or lower their blood pressure by at least 5 mmHg. The therapy is noninvasive and painless, ensuring patient safety and comfort. Curespec is a paradigm shift in managing hypertension and chronic kidney disease, bringing hope to millions of individuals worldwide. We invite you to join us in this journey by contacting us or visiting our website.

02/10/2026

Sometimes the biggest clinical achievement isn’t improvement - it’s stopping the decline.

Avigdor, an 80-year-old engineer and lecturer, faced a steady drop in eGFR that led to a pre-dialysis diagnosis.

After starting treatment with Curespec, the downward trend finally shifted - and even moved slightly upward.

His story is about a curve that changed direction.
Here’s the short testimonial video.

02/04/2026

Great news! 🎉
We’ve received official approval from the Hainan regulatory authority - and the Nephrospec device is now authorized for clinical use.
Another meaningful milestone on our mission to bring advanced therapeutic technologies to patients and make a real impact on their lives. Proud of the team and all our partners on this journey!

✨ U.S. Pilot Clinical Study – 3 of 5 Patients TreatedWe’re excited to share major progress in our U.S. pilot study, cond...
01/27/2026

✨ U.S. Pilot Clinical Study – 3 of 5 Patients Treated

We’re excited to share major progress in our U.S. pilot study, conducted in collaboration with NephroNet (Atlanta, USA) - a network of more than 400 nephrologists.

Our study is now fully:
✔ IRB-approved
✔ Classified as a Non-Significant Risk (NSR) device
✔ Designed as a 5-patient pilot study
✔ And we’re pleased to report that all 5 patients are enrolled, with 3 already treated.

This marks an important milestone as we continue moving forward with our mission to advance kidney health through innovative non-invasive technology.

Full steam ahead! 🚀

01/22/2026

✨ A meaningful and exciting milestone – our collaborative NephroNet study received official approval in the United States in January 2026!

We are pleased to share that our clinical research, conducted together with NephroNet focused on evaluating electro-hydraulic acoustic therapy to enhance renal blood flow and glomerular filtration in patients with Stage III diabetic nephropathy, received IRB approval in the U.S. in January 2026.

The approval granted by Advarra IRB, allows us to proceed to the next phase of the study following a thorough review of the protocol, informed consent forms, and required modifications. This represents an important step forward for our joint teams and for the patients who may one day benefit from this innovative approach.

We’re proud to continue advancing a novel therapy with the potential to significantly improve outcomes for individuals living with diabetic kidney disease.

A heartfelt thank you to our research team, our partners at NephroNet, collaborators, and everyone who contributed to reaching this milestone.

Now, we move forward — with commitment, optimism, and purpose.

What a day at HealthIL Week!Our booth was buzzing from early morning, and we were truly excited to see how much interest...
01/20/2026

What a day at HealthIL Week!
Our booth was buzzing from early morning, and we were truly excited to see how much interest there is in what we’re building at Curespec. So many meaningful conversations, real curiosity, and a long line of visitors throughout the day - thank you to everyone who stopped by.

We’re heading into the next few weeks with a full calendar and plenty of promising leads.
Looking forward to turning these encounters into collaborations that can genuinely move healthcare forward.

A huge thank you to the organizers and partners who made this event possible and all the amazing teams behind the scenes.

📍 Booth  #302We’re excited to share that Curespec will be taking part in HealthIL Week 2026.If 302 happens to be your lu...
01/15/2026

📍 Booth #302

We’re excited to share that Curespec will be taking part in HealthIL Week 2026.

If 302 happens to be your lucky number, you’re in for a treat, because that’s our booth.

This event brings together some of the most inspiring people and ideas in healthcare, and we’re glad to be part of it.

We’d love to show what we’ve been working on and connect with anyone interested in the future of health innovation.

Looking forward to a great week and to meeting many of you there.

🌍 Hypertension remains the  #1 global driver of cardiovascular and kidney complications.Curespec brings a novel, non-inv...
01/06/2026

🌍

Hypertension remains the #1 global driver of cardiovascular and kidney complications.

Curespec brings a novel, non-invasive solution designed to treat the source, not just the symptoms.

When kidneys function better, blood pressure follows.
Simple. Smart. Transformative.

12/31/2025

As 2025 comes to a close, one thing is clear:✨
the way we approach blood pressure treatment is changing.

In just 40 seconds, we captured a glimpse of a year filled with progress, bold steps, and moments that made people stop and rethink what’s possible.

🎯 Clinical insights that sparked real conversations
🌍 Expansion into new markets
💡 Growing momentum around non-invasive blood pressure solutions

If you haven’t followed our journey this year — this is the perfect moment to catch up ▶️
Wishing our partners, collaborators, and community a healthy, successful, and inspiring 2026.

💡 A New Path to Lower Blood PressureAt Curespec, we’re redefining how hypertension is managed.Our non-invasive NEPHROSPE...
12/18/2025

💡 A New Path to Lower Blood Pressure

At Curespec, we’re redefining how hypertension is managed.

Our non-invasive NEPHROSPEC™ therapy targets kidney microvascular function - delivering a meaningful reduction in blood pressure without drugs or surgery.

For millions living with uncontrolled hypertension, innovation can finally mean relief.

✨Wrapping up an inspiring day at the ICI Meeting December 7-9, 2025✨Yesterday we had the opportunity to present Curespec...
12/10/2025

✨Wrapping up an inspiring day at the ICI Meeting December 7-9, 2025✨

Yesterday we had the opportunity to present Curespec at the
“More from our World - Startups Competition,” and it was truly a great experience.
Our session drew strong interest, and we were delighted to receive thoughtful questions from the audience - a clear sign of the growing attention around innovative, non-invasive solutions for blood pressure reduction.
A huge thank you to the organizers, the judges, and everyone who joined our talk.
We're excited for what's ahead and proud to continue pushing the boundaries of hypertension care.

hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

Address

203 Perry Parkway Suite #6
Gaithersburg, MD
20877

Alerts

Be the first to know and let us send you an email when Curespec posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Curespec:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram